Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ Factual Report
$150.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectrum Pharmaceuticals Inc Highlights Promising Zevalin, Folotyn And Belinostat Clinical Data Presented At Annual Meeting Of American Society Of Hematology


Thursday, 13 Dec 2012 07:00am EST 

Spectrum Pharmaceuticals Inc announced promising clinical data from investigator-sponsored studies of ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, FOLOTYN (pralatrexate injection), and belinostat, Spectrum`s histone deacetylase (HDAC) inhibitor. As reported in poster presentations at the recent 54th Annual Meeting of the American Society of Hematology (ASH), studies of ZEVALIN showed promising results in diverse settings and potential indications, including first-line consolidation in patients with diffuse large B-cell lymphoma (DLBCL); treatment of elderly patients with non-Hodgkin`s lymphoma (NHL), and new drug combinations to treat follicular non-Hodgkin`s lymphoma (fNHL). In addition, preclinical in vivo research showed promising synergistic, anti-tumor activity of FOLOTYN, while a Phase 1 study demonstrated early evidence of activity of belinostat in combination therapy of patients, including those with relapsed or refractory acute leukemia. Spectrum's R&D program for ZEVALIN includes, among other initiatives, two Phase 3 studies that are sponsored or funded by the Company: the Phase 3 ZEST trial for first-line consolidation in patients with newly diagnosed DLBCL and the investigator-sponsored Phase 3 SPINOZA trial for patients with aggressive lymphoma who receive autologous stem cell transplantation (ASCT). 

Company Quote

7.91
0.01 +0.13%
11 Jul 2014